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BACKGROUND: In the wake of the coronavirus disease 2019 (COVID-19) pandemic, access to surgical care for patients with head and 
neck cancer (HNC) is limited and unpredictable. Determining which patients should be prioritized is inherently subjective and difficult 
to assess. The authors have proposed an algorithm to fairly and consistently triage patients and mitigate the risk of adverse outcomes. 
METHODS: Two separate expert panels, a consensus panel (11 participants) and a validation panel (15 participants), were constructed 
among international HNC surgeons. Using a modified Delphi process and RAND Corporation/University of California at Los Angeles 
methodology with 4 consensus rounds and 2 meetings, groupings of high-priority, intermediate-priority, and low-priority indications 
for surgery were established and subdivided. A point-based scoring algorithm was developed, the Surgical Prioritization and Ranking 
Tool and Navigation Aid for Head and Neck Cancer (SPARTAN-HN). Agreement was measured during consensus and for algorithm 
scoring using the Krippendorff alpha. Rankings from the algorithm were compared with expert rankings of 12 case vignettes using the 
Spearman rank correlation coefficient. RESULTS: A total of 62 indications for surgical priority were rated. Weights for each indication 
ranged from −4 to +4 (scale range; −17 to 20). The response rate for the validation exercise was 100%. The SPARTAN-HN demonstrated 
excellent agreement and correlation with expert rankings (Krippendorff alpha, .91 [95% CI, 0.88-0.93]; and rho, 0.81 [95% CI, 0.45-0.95]). 
CONCLUSIONS: The SPARTAN-HN surgical prioritization algorithm consistently stratifies patients requiring HNC surgical care in the 
COVID-19 era. Formal evaluation and implementation are required. Cancer 2020;126:4895-4904. © 2020 American Cancer Society. 
LAY SUMMARY: 
• Many countries have enacted strict rules regarding the use of hospital resources during the coronavirus disease 2019 (COVID-19)  
pandemic. Facing delays in surgery, patients may experience worse functional outcomes, stage migration, and eventual inoperability.
• Treatment prioritization tools have shown benefit in helping to triage patients equitably with minimal provider cognitive burden.
• The current study sought to develop what to the authors’ knowledge is the first cancer–specific surgical prioritization tool for use in the 
COVID-19 era, the Surgical Prioritization and Ranking Tool and Navigation Aid for Head and Neck Cancer (SPARTAN-HN). This algorithm 
consistently stratifies patients requiring head and neck cancer surgery in the COVID-19 era and provides evidence for the initial uptake 
of the SPARTAN-HN. 
KEYWORDS: coronavirus disease 2019 (COVID-19), delivery of health care, head and neck cancer, health priorities, patient selection, 
surgical procedures, waiting lists.
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INTRODUCTION
On March 11, 2020, the World Health Organization 
declared a global pandemic due to the novel coronavirus, 
severe acute respiratory syndrome coronavirus 2 (SARS-
CoV-2), and the resulting coronavirus disease 2019 
(COVID-19).1 As a result, in many jurisdictions, oper-
ating room capacity has been limited to only emergent or 
urgent surgical procedures.2 Several advisory bodies have 
issued recommendations to safeguard access to oncologic 
surgery while still acknowledging that treatment delays 
may be necessary. The American College of Surgeons has 
recommended postponing elective surgery, including for 
patients with low-risk cancers, while recommending that 
other urgent cancer surgeries proceed.3,4 Cancer Care 
Ontario has issued similar guidance recommending that 
hospitals include cancer surgery in their care delivery 
plan.5
The time from the diagnosis of head and neck can-
cer (HNC) to surgery is a metric with prognostic impor-
tance, with treatment delays portending poorer oncologic 
outcomes.6-8 In a recent systematic review evaluating 
 delays in time from diagnosis to treatment initiation, 9 
of 13 studies demonstrated a decrease in survival to be 
associated with treatment delays.6-8 These data support 
the urgency of initiating treatment for patients with 
HNC, but to our knowledge do not inform a stratifica-
tion schema when operating room access is not available 
for all patients.
As a result of these new imposed constraints, 
 difficult decisions regarding prioritization for cancer 
surgery are obligatory, and require the consideration 
of broader principles regarding scarce resource allo-
cation.9 Key among these is the need for consistency 
and transparency to achieve fairness and to avoid en-
gendering disparities in both access and outcomes.10,11 
Prioritization on a case-by-case basis using expert clin-
ical judgment can be logistically challenging, carries 
a cognitive burden, and is susceptible to the biases of 
practitioners.
Surgical prioritization tools or algorithms offer de-
cision-making transparency and provide equitable and 
time-sensitive access to care to the patients who need it 
most.12,13 Although tools for surgical prioritization in the 
era of COVID-19 continue to emerge, to our knowledge 
oncology patients have not been explicitly considered.14 
Herein, we have presented the development and vali-
dation of a novel algorithm, Surgical Prioritization and 
Ranking Tool and Navigation Aid for Head and Neck 
Cancer (SPARTAN-HN), for the prioritization of surgery 
for patients with HNC.
MATERIALS AND METHODS
The current study was granted a waiver (20-0463) 
from the research ethics board at the University Health 
Network.
Participants and Setting
For instrument development, a group of 11 expert 
HNC surgeons (J.R.D., D.P.G., R.G., J.C.I., D.B.C., 
D.B., A.E., D.J.E., K.M.H., E.M., and I.J.W.) from 3 
institutions (University Health Network, Sinai Health 
Systems, and Sunnybrook Health Sciences Centre) at 
the University of Toronto participated in the consensus 
process (consensus panel). At the time of the consensus 
process, all 3 institutions were operating under significant 
resource constraints with limited availability of operating 
room time. For instrument validation, a group of 5 par-
ticipants (J.R.D., C.W.N., D.F., D.P.G., and E.M.) com-
pleted the scoring algorithm designed after the consensus 
process. Fifteen external head and neck surgeons (H.Z., 
A.C.N., R.J.W., M.A.C., C.M., E.M.G., V.D., A.G.S., 
A.J.R., C.M.L., E.Y.H., J.M., V.P., B.M., and E.G.) from 
10 institutions across Canada (2 institutions), the United 
States (7 institutions), and the United Kingdom (1 insti-
tution) participated in a ranking exercise of clinical vi-
gnettes (validation panel).
Scope
The scope of variables considered in the prioritization 
algorithm was established and vetted by the consensus 
panel (see Supporting Information 1). All indications for 
prioritization were presented to the consensus panel using 
an online survey platform (Google Forms; https://docs.
google.com/forms). With 2 exceptions, survey respond-
ents were asked to consider each of the indications in iso-
lation. For wait times, panel members were asked to also 
consider histologic grade. Similarly, for surgical site, the 
panel was asked to simultaneously consider extent of sur-
gery. Related indications were presented sequentially to 
facilitate pairwise comparison (eg, stage I and II vs stage 
III and IV were presented in sequence; AJCC 8th edi-
tion). The list of indications was pilot tested by 4 surgeons 
(J.R.D., D.P.G., E.M., and R.G.) for sensibility (readabil-
ity, content validity, language, and comprehensibility).
Consensus Process
The consensus panel participated in a Delphi consen-
sus process with 4 rounds of rating (see Supporting 
Information 2). The first 2 rounds aimed to achieve con-
sensus regarding the priority grouping (high, intermedi-
ate, or low). High priority was defined as an indication to 
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proceed to surgery within 2 weeks. The second 2 rounds 
of rating involved ranking each indication (less impor-
tant, neutral, or more important) within their respective 
priority grouping. Two teleconference meetings were con-
ducted between the first and second rounds and between 
the third and fourth rounds with anonymized results 
from the prior round presented for discussion and to ad-
dress inconsistencies and misinterpretations.
A modification of the RAND/University of 
California at Los Angeles (UCLA) method was used to 
achieve consensus.15 This methodology typically is used 
to determine the appropriateness of an intervention but 
in this setting was used to determine surgical priority. We 
used a scale ranging from 0 to 9 in rounds 1 and 2 to indi-
cate the decision to not operate (0) or low priority (scores 
1-3), intermediate priority (scores 4-6), or high priority 
(scores 7-9). For rounds 3 and 4, we used a scale from 1 
to 9 to rate each indication compared with other indica-
tions within each of the priority groupings as either less 
important (1-3), neutral (4-6), or more important (7-9).
Consensus was determined based on RAND/UCLA 
criteria.15 For the first 2 rounds to determine surgical pri-
ority, a hierarchical logic was adopted to determine con-
sensus regarding whether surgery should be performed, 
and to then determine the priority of surgery based on 
the given indication. Agreement on the decision to not 
operate was defined as a minimum of 8 of the 11 panelists 
rating a given indication with a zero score. If there was no 
agreement to avoid surgery, agreement for surgical prior-
ity then was defined as ≤3 panelists rating the indication 
outside the 3-point range containing the median, as per 
RAND/UCLA guidelines.15 For rounds 1 and 2, any in-
dication that failed to achieve consensus was classified as 
being of intermediate priority, and for rounds 3 and 4, 
any indication failing to achieve consensus was classified 
as neutral within the priority grouping.
Development of the SPARTAN-HN
The algorithm uses a point-based system to assign a total 
score based on the sum of the individual indication scores 
(see Supporting Information 3), with higher scores cor-
responding to higher priority. Scoring weights were based 
on consensus from both sets of rounds such that high-pri-
ority indications were assigned scores ranging from +2 to 
+4, intermediate-priority indications were assigned scores 
ranging from −1 to +1, and low-priority indications were 
assigned scores ranging from −2 to −4. Within each pri-
ority grouping 3-point range, the scores were assigned 
based on the consensus ratings from the third and fourth 
rounds. For any 2 patients with the same total score, the 
patient with the longer surgical wait time was assigned the 
higher priority rank.
Clinical Vignettes
Twelve clinical vignettes were constructed (see 
Supporting Information 4) after the consensus rounds 
to validate the SPARTAN-HN. The vignettes described 
a variety of clinical scenarios incorporating multiple 
prioritization indications and additional clinical in-
formation. Experts were asked to consider only the 
patient-level information provided to them and not 
their own unique clinical and community practice en-
vironments. Twelve scenarios were selected for diversity 
of cases. The number was considered appropriate while 
avoiding the excessive cognitive burden associated with 
ranking too many scenarios.
Statistical Analysis
Agreement
Agreement between raters during the Delphi process was 
calculated at each round and within each priority group-
ing using the Krippendorff alpha (K-alpha). Because typi-
cal coefficients of reliability are not suitable for coded 
data, agreement for the rank orders generated by 5 coders 
(J.R.D., C.W.N., D.F., E.M., and D.P.G.) applying the 
SPARTAN-HN algorithm to the 12 clinical vignettes was 
assessed using K-alpha, calculated with 1000 bootstrap 
samples.16 The K-alpha allows for estimation of reliability 
for any number of raters and categories, and may be used 
when there are missing data.17
Validity of the SPARTAN-HN Algorithm
Convergent validity of the median rankings from the 5 
coders of each of the 12 vignettes using the SPARTAN-HN 
and the expert panel rankings were assessed using the 
Spearman rank correlation coefficient. The strength of 
the correlation was considered weak if the rho was <0.3, 
moderate if the rho was between 0.3 and 0.7, and strong 
if the rho was >0.7.18
In addition to SPARTAN-HN, a second algo-
rithm using a decision-making flowchart was developed 
(SPARTAN-HN2). The tool and associated performance 
characteristics are included in Supporting Information 5.
Sample Size Considerations
For determination of an adequate sample size for the ex-
pert panel, we assumed that for model validity, there was 
a strong correlation between the model rank order and 
expert rank order (ie, rho ≥0.7), an alpha of .05, power 
of 0.8, and a nonresponse rate of 10%. Therefore, the 
calculated sample size requirement was 15 participants.
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All analyses were 2-sided and statistical significance 
was set at P ≤  .05. Analyses were conducted using SAS 
University Edition 9.4 statistical software (SAS Institute 
Inc, Cary, North Carolina).
RESULTS
Establishing Consensus Priority Groupings (First 
2 Consensus Rounds)
After the first 2 rounds, the panel failed to achieve con-
sensus for any indications that would result in a decision 
to not operate. More than 3 respondents indicated that 
they would not operate for the following indications: 1) 
the availability of alternative nonsurgical treatment with 
a similar prognosis (6 respondents; 54%); 2) poor perfor-
mance status (ie, Eastern Cooperative Oncology Group 
[ECOG] performance status of 3-4) (6 respondents; 
54%); and 3) very severe comorbidity as indicated by a 
non–cancer-specific survival rate of <50% at 1 year (5 
respondents; 45%).
In the first round, consensus was achieved for 15 
indications for surgical prioritization (24%), 8 of which 
(13%) were considered high priority, 4 of which (6%) 
were considered intermediate priority, and 3 of which 
(5%) were considered low priority. After review of first-
round results, consensus was achieved for an additional 
28 indications (45%): 25 indications (40%) were rated 
as being of intermediate priority and 3 indications (5%) 
were rated as low priority (Table 1).
Establishing Ranking Within Each Priority 
Grouping (Second 2 Consensus Rounds)
Of the 6 low-priority indications, consensus for the im-
portance of factors was achieved for 2 scenarios (33%), 
both of which were deemed less important (Table 1). Of 
the 48 intermediate-priority indications, consensus for 
the importance of factors was achieved for 9 (19%) of 
scenarios. Of 8 high-priority factors, consensus for the 
importance of factors was achieved for 4 scenarios (50%), 
all of which were deemed to be more important.
Agreement during consensus rounds was found to 
be weak to moderate for all 4 rounds, ranging from 0.27 
to 0.40. The agreement was similar when measured as per 
priority grouping, in which the K-alpha ranged from 0.32 
to 0.35 (Table 2).
SPARTAN-HN: Surgical Prioritization 
Scoring System
Priority weights for each indication ranged from −4 
to +4, spanning a 9-point range and translated from 
the 2 rounds of priority groupings into 3 categories. 
Four indications were assigned a weight of +4 based 
on consensus that these factors were both high prior-
ity and more important (Supporting Information 2) 
(Table 1). All other high-priority indications were 
assigned a +3 weighted score because there was no con-
sensus that they were either less or more important. For 
intermediate-priority indications, a weighted score of 
+1 was assigned for 7 of the 8 indications deemed to 
be more important by consensus. The other indication 
deemed to be more important (thyroid cancer with tra-
cheal invasion) was assigned a score of +4 because of 
the fact that this indication can be associated with low-
grade histology, which is assigned a negative weighted 
score. Three intermediate-priority indications that were 
rated as more important were resource use indications, 
which generally are colinear. As such, the decision was 
made to assign a maximum score of +1 for the presence 
of any or all of these indications. One intermediate-
priority indication was deemed to be less important 
by consensus and was assigned a score of −1. All other 
intermediate-priority indications were assigned scores 
of 0. For the low-priority indications, those deemed 
to be less important were assigned a weight of −4 and 
all other indications were assigned a weight of −3. The 
total scale score ranged from −17 to +20 (Fig. 1).
Reliability and Validity Assessment
Agreement between the 5 coders for the SPARTAN-HN 
was excellent (K-alpha, .91). Agreement between the 15 
expert raters was moderate (K-alpha, .63) Convergent 
validity was demonstrated by a strong correlation be-
tween the rank orders generated by the SPARTAN-HN 
and external experts (rho, 0.81; 95% CI, 0.45-0.95 
[P  =  .0007]). Agreement between expert rankings and 
SPARTAN-HN rankings for the 12 vignettes is shown 
in Figure 2.
DISCUSSION
In the setting of the COVID-19 pandemic, in which the 
availability of operating room time as well as hospital and 
intensive care unit beds is limited, the prioritization of 
surgical oncology cases is imperative to mitigate down-
stream adverse outcomes.19,20 The current methodology 
was adopted based on expert consensus. In the current 
study, we have proposed the SPARTAN-HN, with the 
objective of providing transparency and facilitating surgi-
cal prioritization for treatment providers.
Creating COVID-19–era allocation schemas that are 
ethically sound is both critical and challenging. Emanuel 
et al have advocated 4 ethical principles with which to 
SPARTAN-HN/de Almeida et al
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guide the allocation of scarce resources: 1) maximizing 
the benefits produced by scarce resources; 2) treating 
people equally; 3) promoting and rewarding instrumen-
tal value; and 4) giving priority to those patients who are 
worst off.9 These have been contextualized for cancer care 
more broadly, and are manifest in the SPARTAN-HN 
algorithm.21 The high-priority indications implicitly em-
brace an underlying premise of saving the most lives and/
or preserving the most life-years. Many procedures for 
patients with HNC are aerosol-generating and increase 
the risk to health care workers and other hospitalized pa-
tients.22 Our process accounted for these by giving con-
sideration to these factors during the consensus process, 
although indications associated with potential exposure 
to health care workers did not emerge as low-priority 
ones. Indications associated with lower resource use did 
achieve consensus for higher importance. This may help 
to avoid the opportunity cost of treating fewer patients 
with longer surgeries.
Anecdotal and institution-specific prioritization 
schemas for patients with HNC and general otolaryngol-
ogy have been suggested.2,13 These parallel similar efforts 
for general surgery, cardiac surgery, and orthopedic sur-
gery.12,13,23-28 In many of these, patients are prioritized by 
the scoring of several criteria and summing of the scores 
to achieve a total patient score. Many of these systems 
have been validated against expert rankings of surgical 
priority.27,28
We used a methodology for developing a point-
based prioritization system, similar to those previously 
described.29 To the best of our knowledge, point-based 
surgical prioritization systems have been very well studied 
to date. Hansen et al previously proposed a methodology 
for developing a point-based prioritization system using 




























































































































































































































































































TABLE 2. Agreement Between Experts During the 
Delphi Process




1 0.38 0.34 0.41 0.34 0.31 0.37
2 0.27 0.24 0.31 0.35 0.32 0.38
3 0.40 0.37 0.43 0.35 0.32 0.38
4 0.34 0.30 0.37 0.32 0.28 0.35
Abbreviations: LCL, lower 95% confidence limit; UCL, upper 95% confidence 
limit.
There were 11 raters and agreement was measured using the Krippendorff 
alpha.
a“Ordinal scale” refers to the scale of 0 to 9 used to rate priority of surgery 
and “Per Priority Group” refers to the low-priority, medium-priority, and high-
priority groups related to the scoring scale.
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using clinical judgment; 2) drafting the criteria and cat-
egories within each criteria; 3) pretesting the criteria and 
categories; 4) consulting with patient groups and other 
clinicians; 5) determining point values for criteria and 
categories; 6) checking the test-retest reliability and face 
validity; and 7) revising the points system as new evidence 
emerges.29 Our approach to the development of the 
SPARTAN-HN was similar. However, given the relatively 
expedited nature of the process, we did not directly 
involve patients.
One method proposed for establishing the priority 
of all indications in a point-based scoring system is known 
as Potentially All Pairwise Rankings of all Alternatives 
(PAPRIKA).30 In the current study, we chose to use the 
RAND/UCLA process instead of pairwise comparison 
to minimize computational burden. We established 62 
FIGURE 1. The Surgical Prioritization and Ranking Tool and Navigation Aid for Head and Neck Cancer (SPARTAN-HN) scoring 
system. ECOG indicates Eastern Cooperative Oncology Group; ENE, extranodal extension.
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indications for surgical prioritization that would cre-
ate an enormous computational burden using pairwise 
comparison methodology. One problem inherent in the 
PAPRIKA methodology is the assumption that all indi-
cations are not equal and can be ranked. However, clin-
ically, certain indications may be equivalent in priority. 
Furthermore, pairwise comparisons assume mutual exclu-
sivity of each of the indications, which is not always the 
case. Use of the RAND/UCLA consensus process avoids 
the need for multiple pairwise comparison and allows for 
consideration of each factor in isolation. The goal of the 
consensus rounds was not to establish a rank order for all 
indications, but mainly to understand which indications 
result in high, intermediate, or low priority.
The SPARTAN-HN algorithm has demonstrated 
preliminary reliability and validity. We demonstrated 
good agreement between raters and the SPARTAN-HN 
algorithm, suggesting minimal interpretive error. Many 
of the high-priority indications accounted for some com-
ponent of interpretation because raters were forced to 
consider imminent disease progression that may result in 
an adverse outcome. Despite the subjective decisions that 
must be made as part of SPARTAN-HN, agreement re-
mained high. In fact, true interrater reliability was found 
to be higher because the K-alpha is a conservative mea-
sure of reliability. Other measures of reliability, such as 
the Kendall coefficient of concordance, tend to overesti-
mate reliability and cannot be applied to missing data.31 
Perhaps most important, the SPARTAN-HN correlated 
highly with expert rankings. With established validity, 
this algorithm may be ready for preliminary clinical use, 
although further testing against real-world data to validate 
it with other cancer outcomes, such as survival, is needed.
The results of the current study must be interpreted 
within the context of the study design. Although exter-
nally validated by other surgeons across North America 
and the United Kingdom, the criteria for which consensus 
was achieved for prioritization were not vetted by patients, 
advocacy groups, or other stakeholders such as medical or 
radiation oncologists. The latter groups represent essen-
tial providers in the multidisciplinary care of patients with 
HNC and may have important insight into the avail-
ability and effectiveness of nonsurgical treatments.19,20 
Nonetheless, the actual prioritization of surgical waitlists 
remains the sole responsibility of surgeons and their prac-
tice partners. In addition, the SPARTAN-HN algorithm 
is intended to assist in making difficult prioritization de-
cisions and is not intended to make recommendations 
for the time frame in which patients should receive treat-
ment. Instead, established guidelines should be adhered 
to for treatment targets. Patient wait times as they relate 
to those targets should be considered when using the 
SPARTAN-HN algorithm. The validation process in the 
current study used expert opinion as the gold standard of 
prioritization, which is potentially biased, and reflected 
the opinions of surgeons practicing in academic medical 
centers from 3 resource-rich nations. Subsequently, use of 
the SPARTAN-HN algorithm in other geographic regions 
FIGURE 2. External validation rank results. A total of 14 experts were asked to rate the 12 scenarios provided (shown on the x-axis) 
and the results were compared with the rank generated by models 1 and 2 (shown on the y-axis). Green shading reflects high priority 
(ranked 1-4), yellow shading indicates medium priority (ranked 5-8), and red shading indicates low priority (ranked 9-12). Asterisk 
denotes ties from the algorithm. SPARTAN-HN indicates Surgical Prioritization and Ranking Tool and Navigation Aid for Head and 
Neck Cancer.
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and health care systems requires additional investigation 
because local treatment paradigms and risk factors may 
vary substantially.
The current study has presented the development 
and validation of a novel algorithm for the prioritization 
of surgery for patients with HNC. Further evaluation of 
its implementation in various practice settings will be 
obligatory. However, the results of the current study have 
provided data with which to inform real-world use, as the 
current pandemic has obviated our ability to more rigor-
ously study the instrument prior to making necessary and 
difficult real-time allocation decisions.
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